Hydrochlorothiazide + Irbesartan

Welcome to Dwaey, specifically on Hydrochlorothiazide + Irbesartan page.
This medicine contains important and useful components, as it consists of
Hydrochlorothiazide + Irbesartan is available in the market in concentration.

Generic Name of Hydrochlorothiazide + Irbesartan - Learn More

Hydrochlorothiazide + Irbesartan

Hydrochlorothiazide + Irbesartan Precaution - What You Need to Know

When combining hydrochlorothiazide (HCTZ) with irbesartan, several precautions should be considered to ensure patient safety. Irbesartan is an angiotensin II receptor blocker (ARB), and HCTZ is a thiazide diuretic, making the combination effective for managing hypertension and fluid retention. However, the combined therapy may lead to additive blood pressure-lowering effects, which could result in symptomatic hypotension, especially in patients who are volume-depleted or salt-depleted. Close monitoring of blood pressure is recommended, especially when initiating therapy.

Patients with a history of renal impairment or pre-existing kidney disease should be closely monitored, as the combination of HCTZ and irbesartan can exacerbate renal dysfunction. The use of this combination should be avoided in patients with bilateral renal artery stenosis, as it may worsen renal function. Electrolyte disturbances, such as hypokalemia, hyponatremia, and hyperkalemia, can occur, and patients should have regular electrolyte monitoring. This combination should be used with caution in pregnant women, especially during the second and third trimesters, due to potential harm to the fetus, such as fetal renal dysfunction or hypotension. Both drugs are contraindicated in pregnancy, and alternative therapies should be considered for pregnant or breastfeeding women. Patients with diabetes should be monitored for any changes in blood glucose levels, as the combination may affect glucose metabolism.

Hydrochlorothiazide + Irbesartan Indication - Uses and Benefits

Hydrochlorothiazide and irbesartan are primarily indicated for the treatment of hypertension. The combination provides dual mechanisms of action to lower blood pressure: HCTZ reduces blood volume and vascular resistance through its diuretic effect, while irbesartan blocks the angiotensin II receptor, preventing vasoconstriction and lowering blood pressure. This combination is beneficial for patients whose blood pressure is not adequately controlled with monotherapy. It is also effective for reducing the risk of cardiovascular events, particularly in patients with other risk factors such as diabetes, heart failure, or chronic kidney disease.

Off-label uses of this combination may include managing certain cases of edema related to heart failure or chronic kidney disease, particularly in patients with proteinuria. Although the combination of HCTZ and irbesartan has not been studied extensively for conditions other than hypertension, it is sometimes used off-label for managing renal complications in diabetic nephropathy, as irbesartan may help slow the progression of kidney disease in these patients.

Hydrochlorothiazide + Irbesartan Contraindications - Important Warnings

Hydrochlorothiazide and irbesartan should not be used in patients with a history of hypersensitivity or allergic reactions to either of the components. The combination is contraindicated in patients with anuria (failure of the kidneys to produce urine) or significant renal impairment (creatinine clearance less than 30 mL/min), as this could lead to worsening kidney function. This combination therapy is also contraindicated in patients with bilateral renal artery stenosis or stenosis of a single kidney, as the effects of both medications on renal blood flow can lead to severe renal dysfunction. Additionally, it should be avoided in pregnant women, particularly in the second and third trimesters, due to potential fetal harm, including renal failure, hypotension, and hyperkalemia. The combination is also contraindicated in patients who are hyperkalemic or those with a history of serious electrolyte imbalances, as both medications can affect potassium levels. It should be used cautiously or avoided in individuals with a history of liver disease, as HCTZ may exacerbate hepatic dysfunction.

Hydrochlorothiazide + Irbesartan Side Effects - What to Expect

The side effects of hydrochlorothiazide and irbesartan typically arise from the effects of both drugs on blood pressure and electrolytes. Common side effects include:
- Hypotension: Especially after the first dose, dizziness or fainting can occur, particularly in volume-depleted individuals.
- Electrolyte imbalances: The use of hydrochlorothiazide may lead to hypokalemia (low potassium), hyponatremia (low sodium), or hypomagnesemia (low magnesium), while irbesartan can occasionally cause hyperkalemia (high potassium), particularly in patients with renal dysfunction.
- Renal dysfunction: Both medications may contribute to impaired kidney function, particularly in patients with pre-existing renal disease. Blood tests to monitor kidney function are recommended.
- Hyperglycemia: Hydrochlorothiazide may cause mild increases in blood glucose levels, which may need to be monitored in diabetic patients.
- Dizziness, fatigue, and headaches: These may occur, especially during the initiation of treatment or when blood pressure drops significantly.
- Angioedema: A rare but serious side effect associated with ARBs like irbesartan, involving swelling of the face, lips, tongue, or throat, which can be life-threatening if left untreated. Immediate medical attention is required.
- Rashes and gastrointestinal symptoms: Some patients may experience rashes, nausea, or abdominal discomfort.

Hydrochlorothiazide + Irbesartan Pregnancy Category ID - Safety Information

3

Hydrochlorothiazide + Irbesartan Mode of Action - How It Works

Hydrochlorothiazide and irbesartan work through complementary mechanisms to lower blood pressure and manage fluid retention. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron in the kidneys, leading to increased excretion of sodium, chloride, and water. This diuretic effect reduces blood volume, thereby lowering blood pressure. On the other hand, irbesartan blocks the angiotensin II type 1 receptor, preventing vasoconstriction and the release of aldosterone, a hormone that promotes sodium and water retention. By blocking the effects of angiotensin II, irbesartan dilates blood vessels and helps lower blood pressure. The combination of these two medications provides a dual approach to controlling hypertension: diuresis (through HCTZ) and vasodilation (through irbesartan). The use of both agents together also reduces the risk of compensatory mechanisms that may offset the antihypertensive effects of either drug alone.

Hydrochlorothiazide + Irbesartan Drug Interactions - What to Avoid

The combination of hydrochlorothiazide and irbesartan can interact with several other medications, potentially affecting their efficacy and safety. Notable drug interactions include:
- Other antihypertensive agents: The combination may potentiate the blood pressure-lowering effects of other antihypertensive drugs (e.g., ACE inhibitors, beta-blockers, calcium channel blockers), leading to an increased risk of hypotension. Blood pressure should be closely monitored.
- Lithium: HCTZ can increase lithium levels by reducing renal clearance, increasing the risk of lithium toxicity when combined with irbesartan. Close monitoring of lithium levels is essential.
- Non-steroidal anti-inflammatory drugs (NSAIDs): NSAIDs can reduce the antihypertensive effects of both HCTZ and irbesartan by impairing renal blood flow. This may lead to reduced efficacy in lowering blood pressure and potential renal dysfunction.
- Potassium-sparing diuretics or potassium supplements: The combination may increase the risk of hyperkalemia when used with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium. Monitoring of serum potassium levels is required.
- Other medications affecting renal function: Drugs that impact renal function (e.g., non-potassium-sparing diuretics, ACE inhibitors, or angiotensin receptor blockers) can increase the risk of renal dysfunction or worsen electrolyte imbalances when combined with this therapy.

Hydrochlorothiazide + Irbesartan Pregnancy Category Note - Key Information

Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters)

Hydrochlorothiazide + Irbesartan Adult Dose - Recommended Dosage

For hypertension, the typical starting dose of the combination of hydrochlorothiazide (12.5 mg) and irbesartan (150 mg) is once daily. Depending on the patient's response, the dose may be increased to 300 mg of irbesartan with 12.5 mg of HCTZ, or the dose of hydrochlorothiazide may be adjusted to a maximum of 25 mg, while irbesartan can be titrated to 300 mg per day. The combination is typically taken orally once a day, with or without food. In patients who have not adequately controlled blood pressure with monotherapy, the combination can be used to achieve better blood pressure control. In cases where the target blood pressure is not reached, doses can be increased or additional antihypertensive agents can be added to the regimen.

Hydrochlorothiazide + Irbesartan Child Dose - Dosage for Children

The combination of hydrochlorothiazide and irbesartan is not commonly used in pediatric populations, as there is limited data on its safety and efficacy in children. For pediatric patients, both medications should be used cautiously and only when clearly indicated, with close monitoring for potential side effects such as electrolyte imbalances and renal function. Pediatric dosing would generally follow the dosing guidelines for the individual components (irbesartan and hydrochlorothiazide) but adjusted according to the child’s age, weight, and renal function. As this combination is not approved for pediatric use, healthcare providers may consider alternative therapies based on individual needs.

Hydrochlorothiazide + Irbesartan Renal Dose - Dosage for Kidney Conditions

In patients with renal impairment, particularly those with a creatinine clearance below 30 mL/min, this combination should be used with caution or avoided. Irbesartan and hydrochlorothiazide both require renal clearance, and impaired kidney function can lead to a build-up of these drugs in the system, increasing the risk of side effects like hyperkalemia and worsening renal dysfunction. For patients with mild to moderate renal impairment, dosing adjustments may be necessary, and careful monitoring of renal function and electrolytes is advised. In these patients, lower doses of irbesartan (e.g., 150 mg) may be considered, and the use of other antihypertensive agents that do not rely on renal excretion may be explored.